Caregen Co.Ltd (214370) - Cash Flow Conversion Efficiency

Latest as of June 2025: 0.019x

Based on the latest financial reports, Caregen Co.Ltd (214370) has a cash flow conversion efficiency ratio of 0.019x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩4.16 Billion ≈ $2.82 Million USD) by net assets (₩216.88 Billion ≈ $146.97 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Caregen Co.Ltd - Cash Flow Conversion Efficiency Trend (2015–2024)

This chart illustrates how Caregen Co.Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Caregen Co.Ltd balance sheet liabilities for a breakdown of total debt and financial obligations.

Caregen Co.Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Caregen Co.Ltd ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Shenyang Jinbei Automotive Co Ltd
SHG:600609
0.204x
Sunway Co Ltd
SHG:603333
-0.019x
Eagle Bancorp Inc
NASDAQ:EGBN
-0.030x
Butterfly Network Inc
NYSE:BFLY
-0.014x
Boozt AB
ST:BOOZT
0.379x
Sumber Tani Agung Resources Tbk PT
JK:STAA
0.115x
Hangzhou Chinastars Reflective Material Co.Ltd.
SHE:301077
N/A
Cementos Pacasmayo S.A.A
F:EPCC
0.123x

Annual Cash Flow Conversion Efficiency for Caregen Co.Ltd (2015–2024)

The table below shows the annual cash flow conversion efficiency of Caregen Co.Ltd from 2015 to 2024. For the full company profile with market capitalisation and key ratios, see market value of Caregen Co.Ltd.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 ₩222.98 Billion
≈ $151.11 Million
₩13.49 Billion
≈ $9.14 Million
0.060x -51.93%
2023-12-31 ₩227.30 Billion
≈ $154.04 Million
₩28.60 Billion
≈ $19.38 Million
0.126x +198.20%
2022-12-31 ₩215.98 Billion
≈ $146.37 Million
₩-27.68 Billion
≈ $-18.76 Million
-0.128x -151.82%
2021-12-31 ₩209.72 Billion
≈ $142.12 Million
₩51.86 Billion
≈ $35.14 Million
0.247x +64.84%
2020-12-31 ₩205.16 Billion
≈ $139.03 Million
₩30.78 Billion
≈ $20.86 Million
0.150x -53.27%
2019-12-31 ₩217.01 Billion
≈ $147.06 Million
₩69.66 Billion
≈ $47.21 Million
0.321x +1063.53%
2018-12-31 ₩204.75 Billion
≈ $138.76 Million
₩-6.82 Billion
≈ $-4.62 Million
-0.033x -116.13%
2017-12-31 ₩231.83 Billion
≈ $157.11 Million
₩47.88 Billion
≈ $32.45 Million
0.207x +403.39%
2016-12-31 ₩234.11 Billion
≈ $158.65 Million
₩-15.94 Billion
≈ $-10.80 Million
-0.068x -1180.76%
2015-12-31 ₩248.87 Billion
≈ $168.66 Million
₩1.57 Billion
≈ $1.06 Million
0.006x --

About Caregen Co.Ltd

KQ:214370 Korea Pharmaceuticals
Market Cap
$767.35 Million
₩1.13 Trillion KRW
Market Cap Rank
#10374 Global
#312 in Korea
Share Price
₩105400.00
Change (1 day)
-0.09%
52-Week Range
₩23400.00 - ₩150100.00
All Time High
₩150100.00
About

Caregen Co., Ltd. engages in the research, development, and commercialization of biomimetic peptides and growth factors worldwide. The company offers cosmeceutical products and food supplements under the Dermaheal, Renokin, Deglusterol, PURILUX, Pelo Baum, Pim-Pim-Paul, Neovert, and PTx brands. It also provides medical devices under the REVOFIL, DR.CYJ, PROSTROLANE, PROSTROLANE B-Series, and CG S… Read more